Theravance Biopharma
Open
$16.63
Prev. Close
$16.65
High
$16.69
Low
$16.63
Market Snapshot
$859.42M
7.5
-1.15
$64.38M
90
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Recently from Cashu
Theravance Biopharma Faces Investor Challenges After CYPRESS Trial Failure
Theravance Biopharma Faces Challenges Following CYPRESS Trial Outcome Theravance Biopharma recently grapples with the repercussions of its CYPRESS trial, which had aimed to investigate the efficacy of…
Theravance Biopharma Faces Setback After CYPRESS Trial Failure Raises Shareholder Concerns
Theravance Biopharma's CYPRESS Trial Failure: A Risky Gamble Unravels Theravance Biopharma faces a significant challenge following the disappointing results of its Phase 3 CYPRESS trial, announced on…
Theravance Biopharma Hit Hard by CYPRESS Trial Failure and Investor Discontent
### Theravance Biopharma Faces Backlash After CYPRESS Trial Failure Theravance Biopharma confronts significant challenges following the disappointing results from its CYPRESS Phase 3 clinical trial, w…
Theravance Biopharma’s CYPRESS Trial Failure Triggers 26% Drop in Shareholder Confidence
Theravance Biopharma Faces Major Setback in CYPRESS Trial Theravance Biopharma encounters a critical challenge following the failure of its Phase 3 CYPRESS trial, a pivotal study that significantly im…